{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:01:20Z","timestamp":1790226080410,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The tumor immune microenvironment (TME) of diffuse large B-cell lymphoma (DLBCL) displays pronounced heterogeneity, and existing immunotherapeutic approaches achieve only suboptimal outcomes for a considerable proportion of affected individuals. CD161\u2014a C-type lectin receptor whose coding gene is KLRB1\u2014has lately emerged as a modulator of T-cell activity in several malignancies; nonetheless, a thorough characterization of its function in DLBCL has not yet been undertaken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Transcriptomic analyses quantified KLRB1 mRNA, whereas flow cytometry and immunoblotting assessed its encoded surface protein, CD161. Transcriptomic, genomic, epigenomic (methylation), and exploratory single-cell RNA-sequencing datasets from DLBCL cohorts were integrated with\n                      <jats:italic>in vitro<\/jats:italic>\n                      functional assays to characterize clinical associations, immune context, and hypothesis-generating therapeutic relationships.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pan-cancer analysis revealed predominantly inverse associations between KLRB1 mRNA and immunomodulatory features, whereas DLBCL bulk-tumor analyses showed positive correlations with MHC molecules, immune-cell infiltration estimates, CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell effector programs, and immune-checkpoint transcripts. KLRB1 mRNA was higher in ABC than in GCB DLBCL and was associated with vital status at last follow-up and clinical stage. Lower TIDE scores and pharmacogenomic modeling suggested exploratory, context-dependent relationships with immune-checkpoint blockade and drug response; however, the IMvigor210 urothelial carcinoma cohort showed no significant objective-response difference. Single-cell analyses from two biopsies were exploratory. In OCI-LY3 cells, CD161 manipulation altered MHC-I, phospho-mTOR, cytokine secretion, T-cell activation, and fixed-dose drug-induced apoptosis. These two-biopsy single-cell outputs were not treated as reproducible trajectories or validated intercellular signaling networks, and all functional findings remained specific to the OCI-LY3 model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The KLRB1 mRNA\/CD161 protein axis is associated with an immune-inflamed DLBCL phenotype and ABC subtype biology. Its prognostic and treatment-predictive value remains hypothesis-generating and requires validation in multivariable survival models, DLBCL-specific immunotherapy cohorts, additional cell lines, and\n                      <jats:italic>in vivo<\/jats:italic>\n                      systems. Confirmation in a GCB cell line and formal dasatinib and doxorubicin dose-response experiments are specifically required.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2026.1903725","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:30:35Z","timestamp":1790224235000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative multi-omics characterization of KLRB1\/CD161 in diffuse large B-cell lymphoma: associations with immune context, subtype biology, and therapeutic response"],"prefix":"10.3389","volume":"13","author":[{"given":"Erwei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Blood Transfusion, Fuwai Central China Cardiovascular Hospital, Henan Cardiovascular Disease Center (Central China Subcenter of National Center for Cardiovascular Diseases), Central China Fuwai Hospital of Zhengzhou University, Henan Provincial Cardiovascular Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Fuwai Central China Cardiovascular Hospital, Henan Cardiovascular Disease Center (Central China Subcenter of National Center for Cardiovascular Diseases), Central China Fuwai Hospital of Zhengzhou University, Henan Provincial Cardiovascular Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wanyan","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Fuwai Central China Cardiovascular Hospital, Henan Cardiovascular Disease Center (Central China Subcenter of National Center for Cardiovascular Diseases), Central China Fuwai Hospital of Zhengzhou University, Henan Provincial Cardiovascular Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Fuwai Central China Cardiovascular Hospital, Henan Cardiovascular Disease Center (Central China Subcenter of National Center for Cardiovascular Diseases), Central China Fuwai Hospital of Zhengzhou University, Henan Provincial Cardiovascular Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.clml.2022.07.007","article-title":"Impact of chronic kidney disease and acute kidney injury on safety and outcomes of CAR T-Cell therapy in lymphoma patients","volume":"22","author":"Ahmed","year":"2022","journal-title":"Clin. Lymphoma, Myeloma and Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood.2023022882","article-title":"Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies","volume":"143","author":"Alvarez","year":"2024","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.medj.2024.03.007","article-title":"Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas","volume":"5","author":"Arffman","year":"2024","journal-title":"Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1423184","DOI":"10.1080\/2162402X.2017.1423184","article-title":"Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome","volume":"7","author":"Braud","year":"2018","journal-title":"Oncoimmunology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"847576","DOI":"10.3389\/fimmu.2022.847576","article-title":"LLT1-CD161 interaction in cancer: promises and challenges","volume":"13","author":"Braud","year":"2022","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e008694","DOI":"10.1136\/jitc-2023-008694","article-title":"Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5254911","DOI":"10.1155\/2022\/5254911","article-title":"Systematic pan-cancer analysis of KLRB1 with prognostic value and immunological activity across human tumors","volume":"2022","author":"Cheng","year":"2022","journal-title":"J. Immunol. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1080\/07391102.2019.1676825","article-title":"Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation","volume":"38","author":"Du","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e003995","DOI":"10.1136\/jitc-2021-003995","article-title":"CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors","volume":"10","author":"Duurland","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/ajcp\/aqz060","article-title":"CD161 is expressed in a subset of T-Cell prolymphocytic leukemia cases and is useful for disease Follow-up","volume":"152","author":"Gilles","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1002\/cjp2.353","article-title":"Immune checkpoint CD161\/LLT1-associated immunological landscape and diagnostic value in oral squamous cell carcinoma","volume":"10","author":"Hu","year":"2024","journal-title":"J. Pathol. Clin. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"613204","DOI":"10.3389\/fimmu.2020.613204","article-title":"CD8+CD161+ T-Cells: Cytotoxic memory cells with high therapeutic potential","volume":"11","author":"Konduri","year":"2020","journal-title":"Front. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1158\/1078-0432.CCR-19-1105","article-title":"Tumor mutation burden and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin","volume":"25","author":"Lee","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e12370","DOI":"10.1002\/2056-4538.12370","article-title":"Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology","volume":"10","author":"Lee","year":"2024","journal-title":"J. Pathol. Clin. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41588-023-01561-1","article-title":"Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression","volume":"55","author":"Leeman-Neill","year":"2023","journal-title":"Nat. Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/CBM-230325","article-title":"Identification of a prognostic signature based on five ferroptosis-related genes for diffuse large B-cell lymphoma","volume":"40","author":"Li","year":"2024","journal-title":"Cancer Biomark."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","article-title":"Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis","volume":"184","author":"Mathewson","year":"2021","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/cancers13010134","article-title":"The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy","volume":"13","author":"Mpakali","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/ijms22041743","article-title":"The role of mTOR signaling as a therapeutic target in cancer","volume":"22","author":"Popova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","article-title":"Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity","volume":"183","author":"Ringel","year":"2020","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s43152-025-00061-0","article-title":"An overview of latest developments in DLBCL its pathogenesis, immune significance, prognosis and targets","volume":"6","author":"Sarode","year":"2025","journal-title":"Curr. Tissue Microenviron. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","article-title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-024-12166-0","article-title":"Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation","volume":"24","author":"Sun","year":"2024","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3390\/ijms15022157","article-title":"shRNA-mediated XRCC2 gene knockdown efficiently sensitizes colon tumor cells to X-ray irradiation in vitro and in vivo","volume":"15","author":"Wang","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1158\/2326-6066.CIR-22-0454","article-title":"CD161 characterizes an inflamed subset of cytotoxic T lymphocytes associated with prolonged survival in human papillomavirus-driven oropharyngeal cancer","volume":"11","author":"Wei","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/br.2018.1051","article-title":"Computer-aided design of temozolomide derivatives based on alkylglycerone phosphate synthase structure with isothiocyanate and their pharmacokinetic\/toxicity prediction and anti-tumor activity in vitro","volume":"8","author":"Yang","year":"2018","journal-title":"Biomed. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.7150\/jca.63236","article-title":"CD161, a promising immune checkpoint, correlates with patient prognosis: a pan-cancer analysis","volume":"12","author":"Ye","year":"2021","journal-title":"J. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.csbj.2022.01.004","article-title":"Violations of proportional hazard assumption in cox regression model of transcriptomic data in TCGA pan-cancer cohorts","volume":"20","author":"Zeng","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"904614","DOI":"10.3389\/fonc.2022.904614","article-title":"Identification and assessment of necroptosis-related genes in clinical prognosis and immune cells in diffuse large B-Cell lymphoma","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"688215","DOI":"10.3389\/fimmu.2021.688215","article-title":"A pan-cancer analysis of CD161, a potential new immune checkpoint","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"101315","DOI":"10.1016\/j.neo.2026.101315","article-title":"Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: a pan-cancer perspective on precision oncology","volume":"77","author":"Zhu","year":"2026","journal-title":"Neoplasia"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1903725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:30:50Z","timestamp":1790224250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1903725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":39,"alternative-id":["10.3389\/fmolb.2026.1903725"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1903725","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1903725"}}